New test may expand olaparib benefits to more ovarian cancer patients

NCT ID NCT04780945

Terminated Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

First seen Feb 18, 2026 · Last updated Jun 19, 2026 · Updated 15 times

Summary

This study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatment. The study was terminated early, but it aimed to improve how doctors select treatments for recurrent ovarian cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Erasmus Medical Center

Rotterdam, Netherlands
Leiden University Medical Center

Leiden, 2300RC, Netherlands
University Medical Center Groningen

Groningen, Netherlands

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian epithelial tumor ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 MUTATION BRCA1 MUTATION BRCA2 MUTATION BRCA2 MUTATION HOMOLOGOUS RECOMBINATION DEFICIENCY OVARIAN NEOPLASM EPITHELIAL